Zhengye Biotechnology Holding Ltd
Zhengye Biotechnology Holding Ltd is a biotechnology company engaged in the research, development, and commercialization of biopharmaceutical products.
Business. Zhengye Biotechnology Holding Ltd (ZYBT.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the Pharmaceuticals industry. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the NASDAQ stock exchange.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Zhengye Biotechnology Holding Ltd (ZYBT.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the Pharmaceuticals industry. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the NASDAQ stock exchange.
Zhengye Biotechnology has a market capitalization of 28.24 million USD, based on a market price of 0.95 USD per share and 29.73 million shares outstanding. The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
The company's profitability and return metrics are not available for comparison with industry medians, as no financial performance data is disclosed in the valuation snapshot. This lack of data limits the ability to assess its performance relative to peers in the Pharmaceuticals industry.
Zhengye Biotechnology's revenue concentration and geographic exposure are not disclosed in the available data. The company's segmental breakdown is also not available, which limits the ability to assess its diversification across product lines or regions.
The company's growth trajectory is not quantifiable due to the absence of historical revenue data and forward-looking guidance in the available documents. No numeric deltas or outlooks are provided for the current or next fiscal year.
The company's risk profile is marked by low dilution potential, with no significant dilution sources identified in the available documents. However, the absence of balance-sheet data and going-concern language raises concerns about its financial stability.
No recent events, such as filings or transcripts, are disclosed in the available data, which limits the ability to assess the company's recent operational or strategic developments.
- Zhengye Biotechnology has a small market capitalization of 28.24 million USD, indicating limited investor interest or market presence.
- The company's financial performance and return metrics are not disclosed, making it difficult to assess its profitability relative to industry peers.
- No segmental or geographic revenue breakdown is available, limiting visibility into the company's diversification and exposure.
- The company's liquidity risk could not be assessed due to the absence of balance-sheet data and no going-concern language in source documents.
- No recent events or strategic developments are disclosed, which limits the ability to evaluate the company's current direction.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Zhengye Biotechnology Holding Ltd Market data — financials · 2026-05-30
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Gross margin (FY 2025-12-31): 20.5%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -547.8%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 46.9%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -34.8%Derived (calculated)
- Current ratio (FY 2025-12-31): 1.14xDerived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -7.6%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -3.7%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -8.2%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.52xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -92.3%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 1.6%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): -72.7%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -16.9%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -744.0%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -66.0%Derived (calculated)
- Net margin (FY 2025-12-31): -60.0%Derived (calculated)
- Return on equity (FY 2025-12-31): -27.9%Derived (calculated)
- Return on assets (FY 2025-12-31): -16.0%Derived (calculated)
- Operating cash flow (annual): USD 1.91MSEC XBRL filing
- Total assets (annual): USD 62.41MSEC XBRL filing
- Gross profit (annual): USD 3.41MSEC XBRL filing
- Pre-tax income (annual): USD -10.28MSEC XBRL filing
- Total operating expenses (annual): USD 13.5MSEC XBRL filing
- Long-term debt (annual): USD 1.37MSEC XBRL filing